Opportunities for improved cardiovascular disease prevention in oncology patients.
Journal
Current opinion in cardiology
ISSN: 1531-7080
Titre abrégé: Curr Opin Cardiol
Pays: United States
ID NLM: 8608087
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
11
7
2020
medline:
8
1
2021
entrez:
11
7
2020
Statut:
ppublish
Résumé
Cancer patients often have cardiovascular risk factors at the time of cancer diagnosis, which are known to increase the risk of cardiotoxicity. Cancer survivors have significantly higher cardiovascular risk. Current cardiovascular disease prevention guidelines are based on studies that largely excluded these patients. We reviewed recent data regarding cardiovascular disease prevention in this population. Nonpharmacologic therapies aiming to reduce 'lifestyle toxicity' produced by cancer treatments have demonstrated potential to decrease the incidence of adverse outcomes. Exercise before, during and after cancer treatment not only promotes higher quality of life and cardiorespiratory fitness but also reduces adverse cardiovascular outcomes. Lipid and cardiometabolic disease management is paramount but predominantly based on data that excludes these populations of cancer patients and survivors. A comprehensive approach including medical evaluation, prescriptive exercise, cardiac risk factor modification, education, counseling, pharmacologic and behavioral interventions are needed in cancer patients. These interventions constitute the core of cardio-oncology rehabilitation programs, which if implemented appropriately may help reduce cardiovascular events in this population. Knowledge gaps in these areas are starting to be addressed by ongoing clinical trials.
Identifiants
pubmed: 32649353
doi: 10.1097/HCO.0000000000000767
pii: 00001573-202009000-00013
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
531-537Références
Kirkham AA, Beaudry RI, Paterson DI, et al. Curing breast cancer and killing the heart: a novel model to explain elevated cardiovascular disease and mortality risk among women with early stage breast cancer. Prog Cardiovasc Dis 2019; 62:116–126.
Mehta LS, Watson KE, Barac A, et al. American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes ResearchCardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation 2018; 137:e30–e66.
Patnaik JL, Byers T, DiGuiseppi C, et al. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 2011; 13:R64.
Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation 2016; 133:1104–1114.
Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol 2020; [published online ahead of print, 2020 Mar 30] doi: 10.1038/s41569-020-0348-1.
doi: 10.1038/s41569-020-0348-1
Masoudkabir F, Sarrafzadegan N, Gotay C, et al. Cardiovascular disease and cancer: evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis 2017; 263:343–351.
Aboumsallem JP, Moslehi J, de Boer RA. Reverse cardio-oncology: cancer development in patients with cardiovascular disease. J Am Heart Assoc 2020; 9:e013754.
Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol 2020.
Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 2018; 15:505–522.
Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. New Engl J Med 2017; 377:111–121.
Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2017; 35:893–911.
Denlinger CS, Sanft T, Baker KS, et al. Survivorship, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2018; 16:1216–1247.
Kushi LH, Doyle C, McCullough M, et al. American Cancer Society 2010 Nutrition and Physical Activity Guidelines Advisory CommitteeAmerican Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2012; 62:30–67.
Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012; 62:243–274.
Smith JL, Malinauskas BM, Garner KJ, Barber-Heidal K. Factors contributing to weight loss, nutrition-related concerns and advice received by adults undergoing cancer treatment. Adv Med Sci 2008; 53:198–204.
Meyerhardt JA, Giovannucci EL, Ogino S, et al. Physical activity and male colorectal cancer survival. Arch Intern Med 2009; 169:2102–2108.
Cespedes Feliciano EM, Kwan ML, Kushi LH, et al. Adiposity, postdiagnosis weight change, and risk of cardiovascular events among early-stage breast cancer survivors. Breast Cancer Res Treat 2017; 162:549–557.
Karavasiloglou N, Pestoni G, Wanner M, et al. Healthy lifestyle is inversely associated with mortality in cancer survivors: results from the Third National Health and Nutrition Examination Survey (NHANES III). PloS One 2019; 14:e0218048.
Meacham LR, Chow EJ, Ness KK, et al. Cardiovascular risk factors in adult survivors of pediatric cancer--a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 2010; 19:170–181.
Esbenshade AJ, Simmons JH, Koyama T, et al. Body mass index and blood pressure changes over the course of treatment of pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer 2011; 56:372–378.
Chow EJ, Pihoker C, Hunt K, et al. Obesity and hypertension among children after treatment for acute lymphoblastic leukemia. Cancer 2007; 110:2313–2320.
Children's Oncology Group: Long-term follow-up guidelines for survivors of childhood, version 5.0. Available at: http://www.survivorshipguidelines.org. Accessed 3 November 2020
Zarifa A, Albittar A, Kim PY, et al. Cardiac toxicities of anticancer treatments: chemotherapy, targeted therapy and immunotherapy. Curr Opin Cardiol 2019; 34:441–450.
Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96:1788–1795.
Abi Aad S, Pierce M, Barmaimon G, et al. Hypertension induced by chemotherapeutic and immunosuppresive agents: a new challenge. Crit Rev Oncol Hematol 2015; 93:28–35.
Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011; 37:300–311.
Sudasena D, Balanescu DV, Donisan T, et al. Fulminant vascular and cardiac toxicity associated with tyrosine kinase inhibitor sorafenib. Cardiovasc Toxicol 2019; 19:382–387.
Paschke L, Lincke T, Muhlberg K, et al. Myocardial infarction after long-term treatment with a tyrosine kinase inhibitor (TKI) with anti-VEGF receptor activity. Case Rep Endocrinol 2019; 2019: 7927450.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73:e285–e350.
Oren O, Blumenthal RS, Cainzos-Achirica M, Kopecky SL. Dyslipidemia in cancer patients – evolving context, new challenges. 2019. Available at: https://www.acc.org/latest-in-cardiology/articles/2019/09/04/06/43/dyslipidemia-in-cancer-patients. (Accessed 11 March 2020)
Gilchrist SC, Barac A, Ades PA, et al. American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular DiseaseCardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. Circulation 2019; 139:e997–e1012.
Yin AB, Barac A, Thoman W, et al. Cardiovascular prevention strategies in breast cancer. JACC CardioOncol 2019; 1:322–325.
Wang Y, Tao H, Paxton RJ, et al. Postdiagnosis smoking and risk of cardiovascular, cancer, and all-cause mortality in survivors of 10 adult cancers: a prospective cohort study. Am J Cancer Res 2019; 9:2493–2514.
Taylor C, Correa C, Duane FK, et al. Early Breast Cancer Trialists’ Collaborative GroupEstimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol 2017; 35:1641–1649.
Wadhwa D, Fallah-Rad N, Grenier D, et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat 2009; 117:357–364.
Kelly CM, Shahrokni A. Moving beyond Karnofsky and ECOG performance status assessments with new technologies. J Oncol 2016; 2016: 6186543.
Azam F, Latif MF, Farooq A, et al. Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol 2019; 12:728–736.
Chow R, Bruera E, Temel JS, et al. Inter-rater reliability in performance status assessment among healthcare professionals: an updated systematic review and meta-analysis. Support Care Cancer 2020; 28:2071–2078.
Johnson MJ, Bland JM, Davidson PM, et al. The relationship between two performance scales: New York Heart Association Classification and Karnofsky Performance Status Scale. J Pain Symptom Manage 2014; 47:652–658.
Schmidt K, Vogt L, Thiel C, et al. Validity of the six-minute walk test in cancer patients. Int J Sports Med 2013; 34:631–636.
Blaha MJ, Mortensen MB, Kianoush S, et al. Coronary artery calcium scoring: is it time for a change in methodology? JACC Cardiovasc Imaging 2017; 10:923–937.
Rozanski A, Gransar H, Shaw LJ, et al. Impact of coronary artery calcium scanning on coronary risk factors and downstream testing the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial. J Am Coll Cardiol 2011; 57:1622–1632.
Milgrom SA, Varghese B, Gladish GW, et al. Coronary artery dose-volume parameters predict risk of calcification after radiation therapy. J Cardiovasc Imaging 2019; 27:268–279.
Layoun ME, Yang EH, Herrmann J, et al. Applications of cardiac computed tomography in the cardio-oncology population. Curr Treat Options Oncol 2019; 20:47.
Cuddy PD, Murphy DJ, Dunne RM, et al. Incidental coronary artery calcification in cancer imaging. JACC Cardiooncol 2019; 1:135–137.
Bao PP, Zheng Y, Nechuta S, et al. Exercise after diagnosis and metabolic syndrome among breast cancer survivors: a report from the Shanghai Breast Cancer Survival Study. Cancer Causes Control 2013; 24:1747–1756.
Ibrahim EM, Al-Homaidh A. Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies. Med Oncol 2011; 28:753–765.
Meyerhardt JA, Giovannucci EL, Holmes MD, et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol 2006; 24:3527–3534.
Scott JM, Zabor EC, Schwitzer E, et al. Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: a systematic review and meta-analysis. J Clin Oncol 2018; 36:2297–2305.
Freisling H, Viallon V, Lennon H, et al. Lifestyle factors and risk of multimorbidity of cancer and cardiometabolic diseases: a multinational cohort study. BMC Med 2020; 18:5.
Raffaghello L, Lee C, Safdie FM, et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A 2008; 105:8215–8220.
Passarelli MN, Newcomb PA, Hampton JM, et al. Cigarette smoking before and after breast cancer diagnosis: mortality from breast cancer and smoking-related diseases. J Clin Oncol 2016; 34:1315–1322.
Parada H Jr, Bradshaw PT, Steck SE, et al. Postdiagnosis changes in cigarette smoking and survival following breast cancer. JNCI Cancer Spectrum 2017; 1:pkx001doi: 10.1093/jncics/pkx001.
doi: 10.1093/jncics/pkx001
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018; 71:e127–e248.
Guglin M, Krischer J, Tamura R, et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol 2019; 73:2859–2868.
Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J 2013; 34:1102–1111.
Souza VB, Silva EN, Ribeiro ML, Martins Wde A. Hypertension in patients with cancer. Arquivos brasileiros de cardiologia 2015; 104:246–252.
Riihimaki M, Thomsen H, Brandt A, et al. Death causes in breast cancer patients. Ann Oncol 2012; 23:604–610.
Simon MS, Beebe-Dimmer JL, Hastert TA, et al. Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative. Cancer 2018; 124:1798–1807.
Park NJ, Chang Y, Bender C, et al. Cardiovascular disease and mortality after breast cancer in postmenopausal women: results from the Women's Health Initiative. PloS One 2017; 12:e0184174.
Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012; 18:1639–1642.
Chang HM, Moudgil R, Scarabelli T, et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol 2017; 70:2536–2551.
Jones LW, Courneya KS, Mackey JR, et al. Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol 2012; 30:2530–2537.
Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 2016; 37:1671–1680.
Hornsby WE, Douglas PS, West MJ, et al. Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial. Acta Oncol 2014; 53:65–74.
Knobf MT, Jeon S, Smith B, et al. The Yale Fitness Intervention Trial in female cancer survivors: cardiovascular and physiological outcomes. Heart Lung 2017; 46:375–381.
Lipshultz SE, Adams MJ, Colan SD, et al. American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Basic Cardiovascular Sciences, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular RadioloLong-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 2013; 128:1927–1995.
Yeh JM, Ward ZJ, Chaudhry A, et al. Life expectancy of adult survivors of childhood cancer over 3 decades. JAMA Oncol 2020; e195582.
Reulen RC, Winter DL, Frobisher C, et al. British Childhood Cancer Survivor Study Steering GroupLong-term cause-specific mortality among survivors of childhood cancer. JAMA 2010; 304:172–179.
Oeffinger KC, Mertens AC, Sklar CA, et al. Childhood Cancer Survivor StudyChronic health conditions in adult survivors of childhood cancer. New Engl J Med 2006; 355:1572–1582.
Fidler MM, Reulen RC, Henson K, et al. Population-based long-term cardiac-specific mortality among 34 489 five-year survivors of childhood cancer in Great Britain. Circulation 2017; 135:951–963.
Feijen E, Font-Gonzalez A, Van der Pal HJH, et al. DCOG-LATER Study GroupRisk and Temporal changes of heart failure among 5-year childhood cancer survivors: a DCOG-LATER Study. J Am Heart Assoc 2019; 8:e009122.
Yan AP, Chen Y, Henderson TO, et al. Adherence to surveillance for second malignant neoplasms and cardiac dysfunction in childhood cancer survivors: a childhood cancer survivor study. J Clin Oncol 2020; 38:1711–1722.
Smith WA, Li C, Nottage KA, et al. Lifestyle and metabolic syndrome in adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study. Cancer 2014; 120:2742–2750.
Follin C, Thilen U, Osterberg K, et al. Cardiovascular risk, cardiac function, physical activity, and quality of life with and without long-term growth hormone therapy in adult survivors of childhood acute lymphoblastic leukemia. J Clin Endocrinol Metab 2010; 95:3726–3735.
Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004; 22:820–828.
Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002; 20:4517–4522.
Gupta D, Lee Chuy K, Yang JC, et al. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer. J Oncol Pract 2018; 14:580–587.
Melloni C, Roe MT. Androgen deprivation therapy and cardiovascular disease. Urol Oncol 2020; 38:45–52.
Melloni C, Nelson A. Effect of androgen deprivation therapy on metabolic complications and cardiovascular risk. J Cardiovasc Transl Res 2019.
Agarwal M, Canan T, Glover G, et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer. Curr Oncol Rep 2019; 21:91.
Zareba P, Duivenvoorden W, Leong DP, Pinthus JH. Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol 2016; 8:118–129.
Leong DP, Fradet V, Shayegan B, et al. Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC Study. J Urol 2020; 203:1109–1116.
Melloni C SS, Blemings A, Goodman SG, et al. on behalf of the PRONOUNCE InvestigatorsCardiovascular safety of degarelix versus leuprolide for advanced prostate cancer. JACC: Cardiooncol 2020; 2:70–81.